Ad
related to: triple therapy copd treatment guidelineLearn How This COPD Inhaler Option May Help To Reduce Your COPD Flare-Ups. Discover How This Triple Therapy Option May Help To Improve Your COPD Symptoms.
Search results
researchgate.net
- Chronic obstructive pulmonary disease (COPD) treatment strategies call for a tailored approach to patient needs, in which therapies are introduced to relieve symptoms, improve health status and exercise tolerance, and reduce future risk and severity of exacerbations (including prevent disease progression, prevent and treat exacerbations and reduce mortality). 1 Bronchodilator therapy with long-acting muscarinic antagonist (LAMA) and/or long-acting β2-agonist (LABA) is the recommended initial ...
www.ncbi.nlm.nih.gov/pmc/articles/PMC10474219/Clinical Concepts for Triple Therapy Use in Patients with ...
People also ask
What percentage of patients with COPD initiate triple therapy?
Does closed triple therapy affect prescribing patterns in patients with COPD?
Does triple therapy improve lung health in patients with COPD?
Jul 20, 2023 · The most recent (2023) GOLD Report has several updates relevant to COPD treatment, including updated definitions of COPD, recent associations of inhaled pharmacological therapy with mortality, expanded discussion related to inhaled drug delivery and adherence to inhaled medication, and updated recommendations for initial and follow-up pharmacolo...
- Paul D. Terry, Rajiv Dhand
- Pulm Ther. 2023 Sep; 9(3): 345-357.
- 10.1007/s41030-023-00233-z
- 2023/09
Jan 10, 2024 · Research has shown that triple therapy significantly reduces the likelihood of future hospitalizations following moderate and severe exacerbations. The guideline needs to clarify the recommendations that regulate the utilization of triple therapy for patients who have undergone hospitalization due to exacerbation [17, 18].
- 10.2174/0118743064279064231227070344
- 2024
- Open Respir Med J. 2024; 18: e18743064279064.
Aug 28, 2023 · Chronic obstructive pulmonary disease (COPD) treatment strategies call for a tailored approach to patient needs, in which therapies are introduced to relieve symptoms, improve health status and exercise tolerance, and reduce future risk and severity of exacerbations (including prevent disease progression, prevent and treat exacerbations and ...
- 10.2147/COPD.S424128
- 2023
Jun 24, 2020 · Triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg dose), glycopyrrolate, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than...
- Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, R...
- 2020
Nov 6, 2018 · Triple therapy was associated with a significantly reduced rate of moderate or severe exacerbations compared with LAMA monotherapy (rate ratio 0.71, 95% confidence interval 0.60 to 0.85), LAMA and LABA (0.78, 0.70 to 0.88), and ICS and LABA (0.77, 0.66 to 0.91).
- Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu, Weimin Yao
- 2018
Substantial proportions (58%–80%) of COPD patients on triple therapy were found to have GOLD-discordant prescribing of this regimen for the same timeframe. 9,12 Li and colleagues observed that 60% of mostly Medicare patients prescribed triple therapy between 2012 and 2014 had no exacerbations or only a mild one, not requiring hospitalization ...
Over the past 22 years, annual GOLD Reports have documented important changes in guid-ance and recommendations for uniformly treating patients with chronic obstructive pul-monary disease (COPD) with the goal of improving outcomes in patients suffering from this condition.
